Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0024 | 0.0151 | 0.0151 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0048 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0048 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0048 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0048 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0048 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0048 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0048 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0048 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0048 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.003 | 0.2407 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0048 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0048 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0048 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0048 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0024 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0048 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0042 | 0.7743 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0048 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0024 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0048 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0048 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0048 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0042 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0048 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.003 | 0.2407 | 0.2407 |
Trypanosoma cruzi | p450 reductase, putative | 0.0048 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0048 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change of body weight (functional) | = -6 % | Change in body weight in rats after 7 days at 2 mg/kg dose | ChEMBL. | 6815325 |
Change of body weight (functional) | = -4 % | Change in body weight in rats after 7 days at 6 mg/kg dose | ChEMBL. | 6815325 |
Change of body weight (functional) | = -2 % | Change in body weight in rats after 7 days at 6 mg/kg dose | ChEMBL. | 6815325 |
Change of body weight (functional) | = 0 % | Change in body weight in rats after 7 days at 2 mg/kg dose | ChEMBL. | 6815325 |
Change of tumor area (functional) | = -74 % | Change in body weight in rats after 7 days at 6 mg/kg dose | ChEMBL. | 6815325 |
Change of tumor area (functional) | = -24 % | Change in body weight in rats after 7 days at 6 mg/kg dose | ChEMBL. | 6815325 |
Change of tumor area (functional) | = 29 % | Change in body weight in rats after 7 days at 2 mg/kg dose | ChEMBL. | 6815325 |
Change of tumor area (functional) | = 282 % | Change in body weight in rats after 7 days at 2 mg/kg dose | ChEMBL. | 6815325 |
Complete remission (functional) | = 14 % | Complete remission of DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
Complete remission (functional) | = 28 % | Complete remission of DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
Complete remission (functional) | = 35 % | Complete remission of DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
Complete remission (functional) | = 50 % | Complete remission of DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
New tumors (functional) | = 6 | Progression of DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
New tumors (functional) | = 7 | Progression of DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
New tumors (functional) | = 15 | Progression of DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
New tumors (functional) | = 18 | Progression of DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
No. of tumors (functional) | = 26 | Tumour number in DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
No. of tumors (functional) | = 28 | Tumour number in DMBA-induced mammary carcinoma in rats at 6 mg/kg dose | ChEMBL. | 6815325 |
No. of tumors (functional) | = 34 | Tumour number in DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
No. of tumors (functional) | = 35 | Tumour number in DMBA-induced mammary carcinoma in rats at 2 mg/kg dose | ChEMBL. | 6815325 |
Partial remission (functional) | = 11 % | Partial remission of DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Partial remission (functional) | = 14 % | Partial remission of DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Partial remission (functional) | = 26 % | Partial remission of DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Partial remission (functional) | = 53 % | Partial remission of DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Progressed tumors (functional) | = 3 % | Increased total tumour area (>150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Progressed tumors (functional) | = 16 % | Increased total tumour area (>150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Progressed tumors (functional) | = 26 % | Increased total tumour area (>150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Progressed tumors (functional) | = 54 % | Increased total tumour area (>150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
RBA (binding) | = 2.1 | Displacement of [3H]- estradiol from calf uterine estrogen receptor | ChEMBL. | 6815325 |
RBA (binding) | = 8.6 | Displacement of [3H]- estradiol from calf uterine estrogen receptor | ChEMBL. | 6815325 |
RBA (binding) | = 2.1 | Displacement of [3H]- estradiol from calf uterine estrogen receptor | ChEMBL. | 6815325 |
RBA (binding) | = 8.6 | Displacement of [3H]- estradiol from calf uterine estrogen receptor | ChEMBL. | 6815325 |
Static tumors (functional) | = 10 % | Unchanged total tumour area (51-150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Static tumors (functional) | = 16 % | Unchanged total tumour area (51-150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Static tumors (functional) | = 21 % | Unchanged total tumour area (51-150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Static tumors (functional) | = 23 % | Unchanged total tumour area (51-150%) in DMBA-induced mammary carcinoma in rats | ChEMBL. | 6815325 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.